If you live with diabetes (or love someone who does), you already know the “treatment plan” isn’t just a planit’s a full-time group chat
between your body, your food, your schedule, your stress, and the occasional surprise workout known as “running late.”

In 2023, diabetes care took some genuinely meaningful steps forward. Not in the “we invented a new inspirational poster” way, but in the
“your tech can help prevent dangerous lows,” “your meds can do more than just lower A1C,” and “more people can actually access modern tools” way.
This article breaks down the biggest diabetes treatment advancements of 2023what changed, why it mattered, and how these changes showed up in real life.

Quick safety note: This is educational information, not personal medical advice. Diabetes treatment is highly individualizedalways work with a
qualified clinician for decisions about medications, devices, dosing, and targets.

1) Automated Insulin Delivery Took a Big Leap Forward

Automated insulin delivery (AID) systemsoften called “artificial pancreas” or “closed-loop” systemsare designed to adjust insulin delivery using data from a
continuous glucose monitor (CGM). Think of it as your devices working together so you don’t have to manually “pilot” every glucose bump and dip.

The iLet Bionic Pancreas: a new kind of “set it up, then live” approach

In May 2023, the FDA cleared the Beta Bionics iLet system for people ages 6 and older with type 1 diabetes. What made this newsworthy wasn’t just “another pump.”
It was the system’s emphasis on automation and simplified setupaiming to reduce the mental load of constantly calculating and correcting.

Translation: fewer moments where you feel like you’re taking a pop quiz in carbohydrate math… while you’re also trying to eat, talk, parent, work, or be a human.

MiniMed 780G: meal detection and frequent auto-corrections

In 2023, the FDA also approved Medtronic’s MiniMed 780G system, another AID option that uses CGM trends to automate insulin delivery. One headline feature was
more frequent automatic correction dosinghelpful for real life, where meals don’t always go according to the spreadsheet you never made.

Why this mattered in 2023

The American Diabetes Association (ADA) continued to emphasize diabetes technology in its Standards of Care, reflecting growing evidence that CGM and AID can improve
glucose outcomes and reduce hypoglycemia risk for many people. The storyline of 2023 wasn’t “devices exist.” It was “devices are getting smarter, more automated,
and increasingly supported by clinical guidelines.”

2) CGMs Got Smaller, Faster, and More Connected

CGMs have become a cornerstone of modern diabetes management because they show glucose trends in near-real time. In practice, that means fewer “what just happened?”
moments and more “oh, I see where this is going” moments.

Dexcom G7 became available in the U.S.

Dexcom’s G7, cleared by the FDA in late 2022, launched for U.S. users in 2023. The upgrades people cared about were practical: a smaller sensor, faster warmup,
and a streamlined wear experiencechanges that can make “using the device consistently” easier, which is the part that actually changes outcomes.

Abbott’s Libre systems moved toward deeper AID integration

In March 2023, the FDA cleared certain FreeStyle Libre 2 and Libre 3 sensors for integration with automated insulin delivery systems. The big deal here is
interoperability: the diabetes tech world works best when CGMs and pumps can “talk” to each other safely and reliably.

Time in Range became more mainstreamnot just A1C

A1C remains a key measure, but CGM helped push a more nuanced view: Time in Range (how many hours per day glucose stays within a target range)
can reflect day-to-day quality of control and reduce “average looks fine, but the ride was terrifying” situations. In 2023, more clinicians and patients were
treating the CGM report like a useful mapnot a judgmental report card.

3) Medicare Expanded CGM Coverage, Which Is a Treatment Advancement (Yes, Really)

A breakthrough that sits on a shelf because no one can afford it isn’t much of a breakthrough. In 2023, Medicare broadened coverage criteria for CGM, expanding
access for insulin-treated individuals and certain people with problematic hypoglycemia even if they aren’t using insulin.

Why that matters: CGM isn’t just a convenience. For many people, it’s a safety tool that can reduce severe lows, improve treatment decisions, and support better
outcomesespecially when paired with education and clinician follow-up.

Also, this change sent a signal beyond Medicare. Coverage policies often influence broader adoption and normalize CGM as “standard of care” rather than “special gadget.”

4) The First FDA-Approved Donor Islet Cell Therapy: Lantidra

One of the most historic 2023 milestones: the FDA approved Lantidra (donislecel), the first allogeneic (donor-derived) pancreatic islet cell therapy
for certain adults with type 1 diabetes who have repeated episodes of severe hypoglycemia despite intensive management.

This is not a mass-market cure and it’s not for most people with diabetes. It’s a highly specialized therapy with strict eligibility criteria and a complex clinical pathway.
But it matters because it represents a new category of FDA-approved treatment for a population with serious riskpeople whose glucose is dangerously difficult to manage.

Big-picture significance: 2023 made “cell therapy for diabetes” feel less like science fiction and more like a regulated clinical realitystill early, still limited,
but undeniably real.

5) The “More Than Glucose” Era for Type 2 Diabetes Medications

Diabetes meds in 2023 weren’t just about lowering glucose. The conversation increasingly centered on cardiovascular risk, kidney protection,
and weight managementbecause those are major drivers of long-term health in type 2 diabetes.

GLP-1 receptor agonists and SGLT2 inhibitors stayed in the spotlight

By 2023, guidelines strongly reflected a person-centered approach: medication choices should consider comorbidities (like heart disease or chronic kidney disease),
risk of hypoglycemia, weight goals, cost/access, and patient preferencesnot only A1C.

In plain English: the “best” medication isn’t universal. It’s the one that fits your medical needs and your real life (including what your insurance actually covers).

Tirzepatide’s ripple effect on diabetes care

Tirzepatide (brand name Mounjaro for type 2 diabetes) was approved earlier, but 2023 was a year where its impact on clinical conversations became hard to ignore.
It represents a newer class of medication that targets both GIP and GLP-1 pathways and is used (with diet and exercise) to improve glycemic control in adults with type 2 diabetes.

Clinically, many patients and clinicians discussed this category of therapies not just for A1C reduction, but also for meaningful weight loss and related metabolic improvements.
(Important note: these medications can have side effectsoften gastrointestinaland require individualized risk/benefit discussions.)

6) Insulin Affordability Improved in High-Profile Ways

In 2023, insulin affordability became a front-page issue with tangible changes. Multiple manufacturers announced major list price cuts and/or expanded patient assistance
programs. These moves didn’t change insulin’s biologybut they did change whether people could actually obtain it consistently, which is the difference between “treatment”
and “wishful thinking.”

Examples from 2023 included substantial price reduction announcements from major insulin makers and broader attention to out-of-pocket caps in certain insurance contexts.
Access improvements can reduce rationing risk, prevent emergencies, and support more stable diabetes management.

7) Prevention and Earlier Intervention Kept Gaining Momentum

The most underrated diabetes treatment advancement is the one that prevents complicationsor prevents diabetes in the first place.

More focus on identifying risk earlier

Screening and risk identification (like A1C testing for diabetes and prediabetes) is basic, but 2023 continued pushing a more proactive model:
detect risk early, intervene earlier, and reduce long-term damage.

“Stage-based” thinking in type 1 diabetes influenced care conversations

While not new in 2023, the idea that type 1 diabetes can be identified in earlier stages (before symptoms) continued to shape research, screening discussions, and family decision-making.
This matters because earlier identification can support monitoring, education, and access to specialized therapies where appropriate.

8) What Changed for Patients and Clinicians Day-to-Day

The most meaningful advancements are the ones you feel on a random Tuesdaynot only in a clinical trial abstract.

Less guesswork, more pattern recognition

With CGM, many people moved from “I don’t know why that happened” to “I see the pattern: that breakfast spikes me unless I add protein,” or “I drop after soccer practice.”
That’s not a small change; it’s the difference between reacting late and adjusting earlier.

More automationplus a new skill: managing the tech

AID can reduce decision fatigue, but it also introduces device training, troubleshooting, supply management, and data review. In 2023, the diabetes community increasingly treated
“tech literacy” and “support systems” as part of treatmentnot an optional bonus.

Shared decision-making got more practical

2023 guidelines and real-world practice increasingly aligned around one truth: diabetes care works best when patients and clinicians choose treatments together.
The best plan is the one someone can actually followconsistently, safely, and without feeling like they need a PhD in endocrinology to eat a sandwich.

Frequently Asked Questions

Were these advancements only for type 1 diabetes?

No. While AID milestones are closely associated with type 1 diabetes, CGM expansion, medication strategy shifts, and affordability changes strongly affected type 2 diabetes care as well.

Did 2023 “solve” diabetes?

Nobut it improved tools, access, and specialized treatment options. The pattern is progress-by-iteration: better devices, broader coverage, smarter guidelines, and expanding therapy categories.

What’s the “biggest” advancement?

It depends on the person. For someone with severe hypoglycemia, expanded CGM coverage or specialized therapies can be life-changing.
For others, an AID system may reduce daily burden the most. For many, lower insulin costs are the biggest “real-world” breakthrough.

Real-World Experiences: Living Through the 2023 Upgrades (About )

The best way to understand 2023’s diabetes treatment advancements is to imagine how they changed ordinary days.
For many people using older tools, diabetes management used to feel like driving at night with dim headlights: you could see a little, but not enough to feel confident.
CGM made the road brighternot perfect, but clearer. Instead of a handful of fingerstick snapshots, people could see trends. That meant fewer “surprise” highs after meals,
fewer mysterious lows after activity, and more informed conversations at clinic visits.

People starting newer CGM models in 2023 often described the upgrade in unglamorous but meaningful terms: sensors that felt easier to wear, less intrusive, and simpler to insert.
Those details sound small until you remember this is something someone might use every day for years. When a device is easier to use, people are more likely to keep using itand
consistency is where the benefits compound.

Automated insulin delivery brought a different kind of relief: mental relief. Many users describe a constant background taskquietly calculating insulin needs,
correcting highs, preventing lows, and second-guessing everything. AID systems didn’t remove responsibility (people still count carbs, dose meals, and handle site changes),
but they often reduced the feeling that one mistake would spiral into a bad day. Nighttime, in particular, became less stressful for some users and caregivers because the system could
adjust insulin based on CGM trends instead of waiting for a human to wake up and notice a problem.

Clinicians saw changes too. Visits began to include more CGM report reviewsless “tell me your numbers” and more “let’s look at your patterns.”
That shifted the tone from blame to problem-solving. Instead of judging a single A1C number, teams could discuss why glucose rose at specific times or why lows happened on certain days.
For people who felt discouraged by “average” results that didn’t reflect their daily struggle, this was validating: the data showed the work they were doing.

Access improvements were a huge part of the lived experience in 2023. Expanded Medicare CGM coverage meant some people could finally use a CGM who previously couldn’t.
And insulin price announcements mattered because they reduced a terrifying calculation many families faced: “Can we afford the medicine that keeps me alive?”
When treatment becomes more affordable, people can follow safer plans, keep backups, and avoid rationingall of which directly affect outcomes.

Finally, the approval of a donor islet cell therapy (Lantidra) landed emotionally for many in the diabetes community. Even if most people would never qualify for it,
it symbolized progress: new therapeutic categories are possible, regulated, and real. For people who have watched “promising research” come and go,
2023 offered a rare moment where the headline wasn’t hypeit was an FDA approval with a defined clinical use.

Conclusion

The top diabetes treatment advancements in 2023 shared one theme: making diabetes care more doable.
Smarter automation reduced daily burden. Better CGMs improved visibility and safety. Guidelines reinforced person-centered choices that consider heart, kidneys, weight,
and hypoglycemia risk. Affordability efforts helped turn “available treatment” into “actual treatment.” And for a narrow but important group, cell therapy became a newly approved option.

Diabetes care is still complex, but 2023 moved the field forward in ways that showed up in real livesfewer emergencies, more data-driven decisions, and a little more breathing room.

The post Top Diabetes Treatment Advancements in 2023 appeared first on Best Gear Reviews.